Clinical trial • Not applicable • Musculoskeletal
Autologous adipose-derived mesenchymal stem cells in vitro expanded for Degenerative disc disease
Not applicable trial of Autologous adipose-derived mesenchymal stem cells in vitro expanded for Degenerative disc disease.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Degenerative disc disease
- Trial Stage
- Not applicable
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 30-09-2024
- First CTIS Authorization Date
- 15-10-2024
Trial design
Randomised, control group: sham operation — a needle skin puncture is performed on the back to imitate the intradiscal injection. Not applicable trial across 1 site in Denmark.
- Randomised
- Yes
- Comparator
- Control group: sham operation — a needle skin puncture is performed on the back to imitate the intradiscal injection.
- Target Sample Size
- 34
- Trial Duration For Participant
- 730
Eligibility
Recruits 34 No vulnerable populations selected; informed consent forms provided (documents: L1_Informed Consent Form, L1_SubjectInformationSheet_redacted)..
- Pregnancy Exclusion
- Pregnancy or breastfeeding.
- Vulnerable Population
- No vulnerable populations selected; informed consent forms provided (documents: L1_Informed Consent Form, L1_SubjectInformationSheet_redacted).
Inclusion criteria
- {"criterion_text":"- Patients with lumbar back pain (max 2 levels)\n- age 20 to 60 yrs,\n- moderate disc degeneration (Pfirman grade 2-3)"}
Exclusion criteria
- {"criterion_text":"- Patients with lumbar back pain of other apparent reason such as: severe spinal stenosis, herniated disc, spondylolisthesis grade 2 or more.\n- Penicillin allergies.\n- Age <20yrs, >60 yrs.\n- Cognitive impairment.\n- Treatment with cytostatic drugs.\n- High risk of bleeding (bleeding disorder, taking anticoagulants etc.).\n- Previous injections in disc.\n- Pregnancy or breastfeeding.\n- Conditions not compatible with MRI (non-compatible implants, claustrophobia, severe obesity).\n- Tumors, infection or fracture in spine."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Treatment success, pain reduction compared to control group Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure.\n- VAS-score\n- pain diary\n- EQ-5D\n- ODI\n- SF-36\n- LBPRS","definition_or_measurement_approach":"- Treatment success: Timeframe 2 yr, no post-intervention on treated level. No unexpected events by procedure.\n- VAS-score: \n- pain diary: \n- EQ-5D: \n- ODI: \n- SF-36: \n- LBPRS: "}
Secondary endpoints
- {"endpoint_text":"- MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen.","definition_or_measurement_approach":"- MR morphology of disc: height, water content, fat and lipid, lactose, glucose, proteoglycans, collagen."}
Recruitment
- Planned Sample Size
- 34
- Recruitment Window Months
- 31
- Consent Approach
- Informed consent obtained from participant; subject information and informed consent form documents available (L1_Informed Consent Form; L1_SubjectInformationSheet_redacted). No mention of assent or minor consent (participants are aged 20-60).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 34
Denmark
- Earliest CTIS Part Ii Submission Date
- 08-10-2024
- Latest Decision Or Authorization Date
- 27-05-2025
- Processing Time Days
- 231
- Number Of Sites
- 1
- Number Of Participants
- 34
Sites
- Site Name
- Aarhus Universitet (Vennelyst Boulevard 4, Aarhus C)
- Department Name
- Department of Orthopedic surgery
- Contact Person Name
- Haisheng Li
- Contact Person Email
- Haishli4@rm.dk
Sponsor
Primary sponsor
- Full Name
- Aarhus Universitet
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"Codes: 1,9","organisation_type":"Educational Institution"}
- {"country":"Denmark","full_name":"Region Midtjylland","duties_or_roles":"Codes: 14,4","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- MSC, adipose tissue
- Active Substance
- Autologous adipose-derived mesenchymal stem cells in vitro expanded
- Modality
- Cell therapy
- Routes Of Administration
- Intradiscal use
- Route
- Intradiscal
- Authorisation Status
- Unauthorised IMP (Advanced therapy medicinal product)
- Starting Dose
- 20 million cells / 2 mL Ringer Acetate
- Dose Levels
- 20 million cells / 2 mL (single dose)
- Frequency
- Single intradiscal injection
Related trials
Other published trials that may interest you.